Back to Search
Start Over
662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B.
- Source :
-
Annals of Oncology . 2021 Supplement 5, Vol. 32, pS687-S687. 1p. - Publication Year :
- 2021
- Subjects :
- *RENAL cell carcinoma
*PEMBROLIZUMAB
*MAXIMA & minima
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 32
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 152688407
- Full Text :
- https://doi.org/10.1016/j.annonc.2021.08.058